3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
4
Lymphoma
4
Lymphoma, Mantle-Cell
2
Waldenstrom Macroglobulinemia
1
Recurrence
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Diffuse Large B-Cell Lymphoma Refractory
1
Interventions
Cyclophosphamide
155
Rituximab
148
Etoposide
84
fludarabine phosphate
73
Peripheral Blood Stem Cell Transplantation
68
Mycophenolic Acid
63
Busulfan
62
Filgrastim
59
Melphalan
58
Tacrolimus
54
Whole-Body Irradiation
51
Cytarabine
46
fludarabine
45
Radiotherapy
43
Methotrexate
41
Granulocyte Colony-Stimulating Factor
41
Cyclosporine
41
Vincristine
35
Antilymphocyte Serum
35
Carmustine
33
Doxorubicin
29
Prednisone
26
Thiotepa
25
Bendamustine Hydrochloride
24
Methylprednisolone
22
Ifosfamide
22
Dexamethasone
22
thymoglobulin
21
sargramostim
20
plerixafor
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Non-Hodgkin
×
loncastuximab tesirine
×
Clear all
NCT05144009
2025-01-30
LOTIS-9
ADC Therapeutics S.A.
Phase 2
Terminated
41 enrolled
19 charts